Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
20.24
+0.44 (2.22%)
At close: Sep 4, 2026, 4:00 PM EDT
20.50
+0.26 (1.28%)
After-hours: Sep 4, 2026, 7:30 PM EDT
Janux Therapeutics Revenue
Janux Therapeutics had revenue of $10.27M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $24.00M, up 5,366.97% year-over-year. In the year 2025, Janux Therapeutics had annual revenue of $10.00M, down -5.55%.
Revenue (ttm)
$24.00M
Revenue Growth
+5,366.97%
P/S Ratio
51.56
Revenue / Employee
$212,389
Employees
113
Market Cap
1.24B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.00M | -588.00K | -5.55% |
| Dec 31, 2024 | 10.59M | 2.51M | 30.99% |
| Dec 31, 2023 | 8.08M | -529.00K | -6.14% |
| Dec 31, 2022 | 8.61M | 4.98M | 136.79% |
| Dec 31, 2021 | 3.64M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 393.63M |
| Kura Oncology | 77.23M |
| Immatics | 47.65M |
| Monte Rosa Therapeutics | 28.73M |
| Inventiva | 7.94M |
| Odyssey Therapeutics | 99.00K |
JANX News
- 12 days ago - Janux Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research - TheFly
- 4 weeks ago - Janux Therapeutics price target lowered to $35 from $38 at Stifel - TheFly
- 4 weeks ago - Janux Therapeutics price target lowered to $55 from $58 at Guggenheim - TheFly
- 4 weeks ago - Janux Therapeutics reports Q2 EPS (35c), consensus (29c) - TheFly
- 4 weeks ago - Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - Business Wire
- 4 weeks ago - Janux Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Janux Therapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - Janux Therapeutics assumed with a Buy at Truist - TheFly